• Enhances Enovis’ enabling technology ecosystem to include robotic automation capabilities, empowering surgeons with a broader, integrated set of precision tools in the operating room. 
  • Creates a robotics center of excellence in Grenoble, France, a talent rich medical technology hub. 

Dallas, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- – Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, announced today that it has entered into a binding offer to acquire eCential Robotics, a leading developer of enabling technologies and surgical robotics. The acquisition expands the ASTRA™ enabling technology platform with robotic automation capabilities, creating a more comprehensive ecosystem designed to improve surgical precision, streamline workflows, and enhance patient outcomes. 

Under the terms of the agreement, Enovis will acquire eCential Robotics for an upfront enterprise value of €155 million, which corresponds to cash consideration of approximately €176 million to be paid to eCential Robotics’ shareholders at closing, plus up to €35 million in contingent consideration payable upon the achievement of certain milestones. The transaction is expected to close by year-end 2026, subject to regulatory approvals. 

Enovis plans to fund the proposed transaction through a combination of cash on its balance sheet and availability under its existing revolving credit facility. With regards to adjusted EBITDA margins, we expect approximately 150 basis points of deal related dilution to adjusted EBITDA margin in 2027, offset by approximately 50 basis points of underlying improvement, equating to a 100 basis point headwind in 2027.  Enovis expects to return to year-over-year margin improvement in 2028.  Free cash flow conversion is expected to increase to 50% in 2027, to over $100 million, and further improve in 2028 and 2029.